How Analysts Feel About Abeona Therapeutics Inc (NASDAQ:ABEO) After Decrease in Sellers?

Abeona Therapeutics Inc. (NASDAQ:ABEO) Logo

The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) registered a decrease of 4.64% in short interest. ABEO’s total short interest was 6.61 million shares in September as published by FINRA. Its down 4.64% from 6.94M shares, reported previously. With 583,900 shares average volume, it will take short sellers 11 days to cover their ABEO’s short positions. The short interest to Abeona Therapeutics Inc’s float is 20.66%.

The stock decreased 1.58% or $0.05 during the last trading session, reaching $3.12. About 889,026 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has declined 81.09% since September 12, 2018 and is downtrending. It has underperformed by 81.09% the S&P500.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $151.44 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Among 4 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Abeona Therapeutics has $30 highest and $200 lowest target. $17.17’s average target is 450.32% above currents $3.12 stock price. Abeona Therapeutics had 13 analyst reports since March 18, 2019 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, March 20 by Mizuho. The firm earned “Buy” rating on Wednesday, March 20 by Maxim Group. Cantor Fitzgerald maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) on Tuesday, March 19 with “Buy” rating. SunTrust initiated the stock with “Buy” rating in Wednesday, June 19 report. H.C. Wainwright maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) on Wednesday, March 20 with “Buy” rating. The rating was maintained by RBC Capital Markets on Wednesday, March 20 with “Buy”. Cantor Fitzgerald downgraded it to “Neutral” rating and $200 target in Monday, August 12 report.

More notable recent Abeona Therapeutics Inc. (NASDAQ:ABEO) news were published by: which released: “Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates – Nasdaq” on August 09, 2019, also with their article: “Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB) – GlobeNewswire” published on April 04, 2019, published: “The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight – Yahoo Finance” on September 08, 2019. More interesting news about Abeona Therapeutics Inc. (NASDAQ:ABEO) were released by: and their article: “Abeona Therapeutics Appoints Dr. Victor Paulus Senior Vice President of Regulatory Affairs – GlobeNewswire” published on June 26, 2019 as well as‘s news article titled: “Abeona Therapeutics: A True Test Looms As Cash Dwindles – Seeking Alpha” with publication date: July 17, 2019.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.